0001193125-21-244725.txt : 20210812 0001193125-21-244725.hdr.sgml : 20210812 20210812162308 ACCESSION NUMBER: 0001193125-21-244725 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20210812 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210812 DATE AS OF CHANGE: 20210812 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Tempest Therapeutics, Inc. CENTRAL INDEX KEY: 0001544227 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 451472564 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35890 FILM NUMBER: 211167911 BUSINESS ADDRESS: STREET 1: 7000 SHORELINE COURT STREET 2: SUITE 275 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 415-798-8589 MAIL ADDRESS: STREET 1: 7000 SHORELINE COURT STREET 2: SUITE 275 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: Millendo Therapeutics, Inc. DATE OF NAME CHANGE: 20181207 FORMER COMPANY: FORMER CONFORMED NAME: OvaScience, Inc. DATE OF NAME CHANGE: 20120308 8-K 1 d186207d8k.htm 8-K 8-K
NASDAQ false 0001544227 0001544227 2021-08-12 2021-08-12

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 12, 2021

 

 

TEMPEST THERAPEUTICS, INC.

(Exact name of Registrant as Specified in its Charter)

 

 

 

Delaware   001-35890   45-1472564
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

7000 Shoreline Court, Suite 275

South San Francisco, CA 94080

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (415) 798-8589

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange
on which registered

Common Stock, par value $0.001 per share   TPST   The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 2.02 Results of Operations and Financial Condition.

On August 12, 2021, Tempest Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the second fiscal quarter ended June 30, 2021. A copy of the Company’s press release dated August 12, 2021, titled “Tempest Reports Second Quarter 2021 Financial Results and Provides Corporate Highlights” is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The foregoing information (including the exhibit hereto) is being furnished under “Item 2.02 Results of Operations and Financial Condition” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers

Appointment of Directors

Effective as of August 6, 2021, the Company’s Board of Directors (the “Board”) appointed Ronit Simantov, M.D. to serve as Class III director of the Board. Class III directors serve until the 2024 annual meeting of stockholders. There is no arrangement or understanding between Dr. Simantov and us, or any other person, pursuant to which she was appointed as a director.

Dr. Simantov will receive compensation consistent with the Company’s Non-Employee Director Compensation Policy (the “Non-Employee Director Compensation Policy”), which provides for annual cash compensation of $40,000 for service on the Board. In addition, pursuant to the Non-Employee Director Compensation Policy, Dr. Simantov (a) was granted an option to purchase 6,635 shares of the Company’s common stock, pursuant to which one third of the shares subject to the option will vest on the one-year anniversary of the date of grant and the remaining two thirds will vest in equal monthly installments over the 24 months thereafter, and (b) will be granted an option to purchase 3,318 shares of the Company’s common stock following each annual meeting of stockholders commencing with the 2022 annual meeting of stockholders, pursuant to which 100% of the shares subject to the option will vest on the earlier of (i) one-year anniversary of the date of grant or (ii) the date of the Company’s annual meeting of stockholders for the year subsequent to the year such grant is made. Further, Dr. Simantov will enter into the Company’s standard form of indemnification agreement providing for indemnification, subject to certain limitations, by the Company in connection with her service as a director of the Company.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit No.

   

Description

99.1    Press release dated August 12, 2021
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    TEMPEST THERAPEUTICS, INC.
Date: August 12, 2021     By:  

  /s/ Stephen Brady

    Name:     Stephen Brady
    Title:     Chief Executive Officer
 EX-99.1 2 d186207dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Tempest Reports Second Quarter 2021 Financial Results and

Provides Corporate Highlights

 

  •  

Closed merger transaction resulting in public listing (TPST)

 

  •  

Closed $30M PIPE, extending runway into Q1’23

 

  •  

Advancing TPST-1495 and TPST-1120 into targeted patient populations

 

  •  

Advanced TREX-1 program to potent lead series with in vivo efficacy

South San Francisco, CA, August 12, 2021 – Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results and provided a corporate update for the second quarter ended June 30, 2021.

“The second quarter of 2021 was an exciting period as Tempest became a public company and the team drove progress in all three of our novel programs,” said Steve Brady, chief executive officer of Tempest. “We look forward to the planned opening of the TPST-1120 randomized study in first line hepatocellular carcinoma in collaboration with Roche and the first combination study of TPST-1495, and remain focused on delivering potentially value-creating milestones over the next year and beyond.”

Recent Highlights

 

  •  

Public Company Transition: successfully closed merger and concurrent PIPE financing, allowing Tempest to become a public company listed on the Nasdaq Capital Market, and extending runway into 2023 through multiple potential catalysts.

 

  •  

TPST-1495 (clinical dual EP2/4 prostaglandin receptor antagonist): continued enrollment in monotherapy dose optimization towards recommended Phase 2 dose (“RP2D”).

 

  •  

TPST-1120 (clinical PPARα antagonist): (i) completed monotherapy dose escalation and selected 600mg BID as RP2D; (ii) observed stable disease (“SD”) in 50% of the monotherapy-treated patients, including prolonged SD in patients with refractory cholangiocarcinoma; and (iii) observed a deep, confirmed partial response in a patient with checkpoint inhibitor-refractory fourth line renal cell carcinoma in the combination study with nivolumab (->60% by RECIST 1.1, durable through 4 scans and ongoing).

  •  

TREX-1 Inhibitor (preclinical, tumor-selective STING pathway activator): (i) progressed lead series to picomolar IC50 potency in biochemical assays; and (ii) demonstrated significant proof of concept in a mouse tumor model with systemic delivery of a lead series molecule.

 

  •  

Board of Directors: Christine Pellizzari, J.D., Geoff Nichol, M.B., Ch.B., M.B.A., and Ronit Simantov, M.D., joined the Board of Directors, bringing deeper financial, legal, and clinical development expertise to Tempest.

Planned Near-Term Milestones

 

  •  

TPST-1495 (clinical dual EP2/4 prostaglandin receptor antagonist): (i) selection of monotherapy RP2D expected in the first half of 2022; (ii) commencement of a combination study with an anti-PD-1 checkpoint inhibitor expected prior to the end of 2021; and (iii) commencement of monotherapy expansion in targeted indications and biomarker-selected patient populations expected in the first half of 2022.

 

  •  

TPST-1120 (clinical PPARα antagonist): (i) identification of RP2D of TPST-1120 in combination with nivolumab expected prior to the end of 2021; and (ii) commencement of first line randomized Phase 1b/2 study in hepatocellular carcinoma patients, under a collaboration with F. Hoffman La Roche, expected within the third quarter.

 

  •  

TREX-1 Inhibitor (preclinical tumor-selective STING pathway activator): planned selection of development candidate in the first half of 2022.

Financial Results

Second Quarter

 

  •  

Tempest ended the second quarter of 2021 with $68.5 million in cash and cash equivalents and short-term restricted cash, compared to $18.8 million in December 31, 2020. The increase was primarily due to the merger and concurrent PIPE, which closed in June 2021.

 

  •  

Net loss and net loss per share for the second quarter of 2021 were $7.1 million and $7.63, respectively, compared to $5.2 million and $11.42, respectively, for the second quarter of 2020. The increase was primarily due to an increase in compensation expense and professional fees associated with the merger.

  •  

Research and development expenses for the second quarter of 2021 were $4.2 million, compared to $4.1 million for the same period in 2020. The $0.1 million increase was primarily attributable to increased compensation expenses.

 

  •  

For the three months ended June 30, 2021, general and administrative expenses were $2.6 million compared to $1.1 million for the same period in 2020. The increase was primarily due to growth in compensation expense and professional fees associated with the merger.

Year-to-Date

 

  •  

Net cash used in operations for the six months ended June 30, 2021 was $6.2 million.

 

  •  

Net loss and net loss per share for the six months ended June 30, 2021 were $12.4 million and $17.30, respectively, compared to $9.5 million and $21.28, respectively, for the same period in 2020.

 

  •  

Research and development expenses for the six months ended June 30, 2021 were $7.8 million compared to $7.1 million for the same period in 2020. The $0.7 million increase was primarily due to increased compensation expenses and consulting services.

 

  •  

For the six months ended June 30, 2021, general and administrative expenses were $4.1 million compared to $2.4 million for the same period in 2020.

About Tempest Therapeutics

Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s two novel clinical programs are TPST-1495 and TPST-1120, antagonists of EP2/EP4 and PPARα, respectively. Both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate selectively the cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity. Tempest is headquartered in South San Francisco. More information about Tempest can be found on the company’s website at www.tempesttx.com.

Forward-Looking Statements

This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended (the “Securities Act”)) concerning Tempest Therapeutics, Inc. (“Tempest Therapeutics”). These statements may discuss goals, intentions, and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Tempest Therapeutics, as well as assumptions made by, and information currently available to, management of Tempest Therapeutics. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “could”, “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions. All statements that are not historical facts are forward-looking statements, including any statements regarding the timing and selection of development candidates, dose selection or commencement of, or availability of data from, clinical trials, the company’s guidance regarding cash resources as well as our operational plans and the timing and ability to deliver on value-creating milestones. Forward-looking statements are based on information available to Tempest Therapeutics as of the date hereof and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement. These and other risks are described in greater detail in the Form 10-Q filed by Tempest Therapeutics with the Securities and Exchange Commission on August 12, 2021. Except as required by applicable law, Tempest Therapeutics undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Tempest Therapeutics’ views as of any date subsequent to the date of this press release and should not be relied upon as prediction of future events. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Tempest Therapeutics.

TEMPEST THERAPEUTICS, INC.

Consolidated Balance Sheets

(in thousands)

 

     June 30, 2021     December 31, 2020  

Assets

     

Current assets

     

Cash and cash equivalents

    $ 68,458     $ 18,820  

Prepaid expenses and other current assets

      2,036       1,005  
  

 

 

    

 

 

  

Total current assets

      70,494       19,825  
  

 

 

    

 

 

  

Property and equipment, net

      1,218       1,110  

Operating lease right-of-use assets

      3,673       1,877  

Other noncurrent assets

      112       51  
  

 

 

    

 

 

  

Total assets

    $ 75,497     $ 22,863  
  

 

 

    

 

 

  

Liabilities and Stockholders’ Equity

     

Current liabilities

     

Accounts payable

    $ 6,695     $ 1,071  

Accrued expenses and other

      1,526       1,439  

Current operating lease liabilities

      1,484       712  

Interest payable

      89       —    
  

 

 

    

 

 

  

Total current liabilities

      9,794       3,222  
  

 

 

    

 

 

  

Loan payable, net

      14,915       —    

Operating lease liabilities

      2,674       1,727  
  

 

 

    

 

 

  

Total liabilities

      27,383       4,949  
  

 

 

    

 

 

  

Convertible preferred stock

      —         86,707  
  

 

 

    

 

 

  

Stockholders’ equity

     

Common stock

      7       15  

Additional paid-in capital

      132,281       2,953  

Accumulated deficit

      (84,174 )      (71,761 ) 
  

 

 

    

 

 

  

Total stockholders’ equity

      48,114       (68,793 ) 
  

 

 

    

 

 

  

Total liabilities, convertible preferred stock and stockholders’ equity

    $ 75,497     $ 22,863  
  

 

 

    

 

 

  

TEMPEST THERAPEUTICS, INC.

Consolidated Statements of Operations

(in thousands except per share amounts)

 

     Three months ended
June 30, 2021		     Three months ended
June 30, 2020		     Six months ended
June 30, 2021		     Six months ended
June 30, 2020		  

Expenses:

         

Research and development

    $ 4,229     $ 4,094     $ 7,821     $ 7,121  

General and administrative

      2,556       1,144       4,091       2,420  
  

 

 

    

 

 

    

 

 

    

 

 

  

Total expenses

      6,785       5,238       11,912       9,541  
  

 

 

    

 

 

    

 

 

    

 

 

  

Operating loss

      (6,785 )      (5,238 )      (11,912 )      (9,541 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Other income (expense), net:

         

Interest expense

      (276 )      —         (507 )      —    

Interest and other income, net

      3       9       6       84  
  

 

 

    

 

 

    

 

 

    

 

 

  

Net loss

    $ (7,058 )    $ (5,229 )    $ (12,413 )    $ (9,457 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Net loss per share

    $ (7.63 )    $ (11.42 )    $ (17.30 )    $ (21.28 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Investor Contacts:

Sylvia Wheeler

Wheelhouse Life Science Advisors

swheeler@wheelhouselsa.com

Aljanae Reynolds

Wheelhouse Life Science Advisors

areynolds@wheelhouselsa.com

###

 

 EX-101.SCH 3 tpst-20210812.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 tpst-20210812_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Security Exchange Name Security Exchange Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 tpst-20210812_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g186207g0812083824973.jpg GRAPHIC begin 644 g186207g0812083824973.jpg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ⅅ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d186207d8k_htm.xml IDEA: XBRL DOCUMENT 0001544227 2021-08-12 2021-08-12 NASDAQ false 0001544227 8-K 2021-08-12 TEMPEST THERAPEUTICS, INC. DE 001-35890 45-1472564 7000 Shoreline Court Suite 275 South San Francisco CA 94080 (415) 798-8589 false false false false Common Stock, par value $0.001 per share TPST false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Aug. 12, 2021
Cover [Abstract]  
Security Exchange Name NASDAQ
Amendment Flag false
Entity Central Index Key 0001544227
Document Type 8-K
Document Period End Date Aug. 12, 2021
Entity Registrant Name TEMPEST THERAPEUTICS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-35890
Entity Tax Identification Number 45-1472564
Entity Address, Address Line One 7000 Shoreline Court
Entity Address, Address Line Two Suite 275
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code (415)
Local Phone Number 798-8589
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol TPST
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://imetrix.edgar-online.com//20210812/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d186207d8k.htm d186207dex991.htm tpst-20210812.xsd tpst-20210812_lab.xml tpst-20210812_pre.xml http://xbrl.sec.gov/dei/2020-01-31 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d186207d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d186207d8k.htm" ] }, "labelLink": { "local": [ "tpst-20210812_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "tpst-20210812_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "tpst-20210812.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "tpst", "nsuri": "http://imetrix.edgar-online.com/20210812", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d186207d8k.htm", "contextRef": "duration_2021-08-12_to_2021-08-12", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://imetrix.edgar-online.com//20210812/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d186207d8k.htm", "contextRef": "duration_2021-08-12_to_2021-08-12", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20210812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001193125-21-244725-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-21-244725-xbrl.zip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